Our previous study indicated that maternal high-estrogen environment in the first trimester is correlated with increased risks of low birth weight (LBW) and adult diseases. The present study aimed to establish an animal model to confirm such an effect in mice, and to further explore the mechanism involved. A mouse model with high estradiol (E 2 ) exposure during early pregnancy was established, and the birth weight, growth after birth, and expression levels of insulin-like growth factorbinding protein 1 (IGFBP1) of pups were examined. Meanwhile, IGFBP1 expression after treatment of E 2 was examined in a HepG2 hepatoma cell line. We found that after exposure to a high-E 2 environment the weight of the pups decreased significantly, not only before but also after birth. Meanwhile, both mRNA and protein expressions of IGFBP1 were elevated in placenta and liver tissues. Furthermore, the level of IGFBP1 in the HepG2 cell line was elevated by the treatment of E 2 , whereas this effect was blocked by estrogen receptor antagonist ICI 182780. In summary, maternal high estrogen upregulates expression of IGFBP1 in placenta and fetal livers, which contributes to LBW and decreases body weight in offspring.
INTRODUCTION
Low birth weight (LBW) is considered a key health indicator that can reflect the events in prenatal life, initiate long-term changes, and increase risks of some diseases [1] [2] [3] [4] .
Growing evidence suggests that offspring conceived through assisted reproductive technology (ART) have LBW, which persists even after adjustment for multiple pregnancy and preterm delivery [5] . Recently a series of studies from Denmark, Finland, the United States, and China compared the birth weight of offspring conceived through fresh embryo transfer (ET) and that of frozen ET; surprisingly, these studies unanimously concluded that the risk of LBW in the fresh ET group increased significantly compared with that in the frozen ET group [6] [7] [8] [9] [10] . These results indicated that uterine exposure to a high-estrogen environment might increase the risk of LBW in offspring. Our recent study discovered that maternal serum estradiol (E 2 ) level on the day of human chorionic gonadotropin administration negatively correlated with birth weight [7] , and this result further demonstrated that maternal high-estrogen exposure might lead to LBW.
However, few studies have been carried out to explore the mechanism underlying this excess risk of LBW caused by high-estrogen exposure. For such a purpose, we recently compared the levels of insulin, insulin-like growth factor 1 (IGF-1), and IGF-2 in umbilical blood between the high-and low-E 2 groups. Disappointingly, none of these factors exhibited significant differences between these two groups [7] . In our previous microarray experiment an increased mRNA expression of insulin-like growth factor-binding protein 1 (IGFBP1) was detected in offspring conceived through fresh ET compared with naturally conceived (NC) offspring (fold change ¼ 2.14), and it was further confirmed by real-time PCR (fresh ET vs. NC: 2.57 6 0.54 vs. 1.00 6 0.14; P , 0.01). These results indicated that IGFBP1 might be involved in LBW induced by maternal high-estrogen exposure.
IGFBP1 is a member of the insulin-like growth factorbinding family, secreted by hepatocytes and other cell types, and binds to both IGF-1 and IGF-2 [11] . Increased IGFBP1 level in umbilical blood was observed in a small for gestational age (SGA) group as early as 1991 [12] . Subsequent studies confirmed the elevated circulating and placental IGFBP1 in fetal growth restriction (FGR) [13] [14] [15] . Fetal growth restriction occurred in transgenic mice overexpressing hIGFBP1, further suggesting that high concentration of circulating IGFBP1 was sufficient to cause FGR [16] . Thus, IGFBP1 might play a pivotal role in the increased risk of LBW after high E 2 exposure.
The purpose of the present study was to establish an animal model of fetal high-estrogen exposure and: 1) confirm whether fetal high-estrogen exposure can lead to LBW in offspring; and 2) explore the possible role of IGFBP1 in such a pathogenesis.
MATERIALS AND METHODS

Establishment of the Mouse Model of Fetal High-Estrogen Exposure
A mouse model of fetal high-E 2 exposure was generated in ICR mice (a strain of albino mice originating in Switzerland and selected by Dr. Hauschka at the Institute for Cancer Research, Philadelphia, PA, to create a fertile mouse line; this strain has a good reproductive performance and fast growth rate, has been used extensively in toxicology and pharmacology studies, and is often used for product safety testing) through an oral supplementation of estradiol valerate (Ev). All animal protocols were reviewed and approved by the Zhejiang University Animal Care and Use Committee. All methods were carried out in accordance with the approved guidelines. All the adult female mice included in this study had regular cycle for at least 2 wk, and at the age of 8 wk virgin females were mated with normal males. Onset of pregnancy was determined by the presence of a copulation plug after overnight mating (designated as Day 0 [D0] of pregnancy). Various doses (0, 10, 50, 100, and 300 lg/kg/day) of Ev (Y0001823; Sigma) were dissolved in corn oil (C8267; Sigma) and orally administrated from D5 to D11 (daily, at 1000 h) to achieve fetal E 2 exposure. Every mouse was fed directly in the mouth with a 20-ll drop of corn oil containing Ev by pipette. To evaluate the serum E 2 level after Ev administration, 30 females (0, 10, 50, 100, and 300 lg/kg/day, respectively, six females per group) were killed on D11 of pregnancy, and blood was collected for measuring the E 2 concentration.
Another 54 mice were randomly assigned to a control group (equal volume of corn oil), a low-E 2 group (Ev10; 10 lg/kg/day), and a high-E 2 group (Ev100; 100 lg/kg/day). Eighteen pregnant females were killed by cervical dislocation on Gestational Day 18 (D18, 1 day before parturition) to obtain placenta and liver samples. Part of the placenta was washed in PBS and stored in liquid nitrogen (À1708C), and the other part was embedded in paraffin. The other 36 pregnant mice were allowed to deliver spontaneously, and the body weight was recorded. Livers were collected on D18, 3 wk after birth, and 8 wk after birth, respectively. The livers were washed in PBS and stored in liquid nitrogen. Three fetuses or pups were randomly picked from each birth for further study.
Serum E 2 Radioimmunoassay
The whole-blood specimens of control and Ev-administrated female mice were collected in a covered test tube by eyeball removal exsanguinations at killing on D11 of pregnancy. After collection of the whole blood, the blood was allowed to clot by leaving it undisturbed at room temperature for 30 min. The clot was removed by centrifuging at 2000 3 g for 10 min in a refrigerated centrifuge. The liquid component (serum) was immediately transferred into a clean polypropylene tube and stored at À808C until analysis. Serum E 2 concentrations were assayed with a liquid scintillation counter (XH6080; Xi'an Nuclear Instrument Factory) by the Beijing North Institute of Biological Technology using an iodine [ 125 I] estradiol radioimmunoassay kit (Beijing North Institute of Biological Technology) according to the manufacturer's instructions. Each test was carried out in three replicate wells. The intraassay and interassay coefficients of variation for the determination of all biochemical variables were less than 10%.
Cell Culture
The human hepatoma cell line HepG2 was obtained from American Type Culture Collection (ATCC) and was used in previous study in our lab [17] . The passage number did not exceed 10 after thawing. HepG2 was cultured in phenol red Dulbecco modified Eagle medium (DMEM; high-glucose medium; 11965-092; Gibco BRL) supplemented with 10% fetal bovine serum (10099-141; Gibco BRL), 100 lg/ml streptomycin, and 100 U/ml penicillin (15070063; Gibco-BRL). Cell cultures were maintained in the environment of 378C and 5% CO 2 . The cells were passaged when they were confluent to 80% in 100-mm dishes (Corning).
For 17b-E 2 treatment, when the cells were confluent to 40%-50% in sixwell plates, the medium was replaced by phenol red-free DMEM (21063029; Gibco-BRL) supplemented with 1% charcoal-stripped fetal bovine serum (GTX73274; Gibco-BRL). HepG2 cells were treated with 0, 10 À9 , 10
À7
, and 10 À5 mol/L 17b-E 2 (E8875; Sigma-Aldrich) for 24 h in the absence or presence of pretreatment of estrogen receptor antagonist ICI 182780 (10 À5 mol/L). The experiments were repeated three times.
Total RNA Extraction and Reverse Transcription
Total RNA was extracted from placental tissues, liver tissues, and HepG2 cells using Trizol reagents (9108; TaKaRa), and reverse transcribed according to the manufacturer's instructions. Briefly, placental or liver tissues were mixed with Trizol reagent (20-50 mg per 1000 ll) and homogenized using a micronizer (Tissuelyser-48; Shanghai Jingxin Co.), under the same conditions of 60 Hz, 60 s. For RNA extraction from HepG2 cells, 0.5 ml of Trizol reagent (for 1 3 10 6 to 5 3 10 6 trypsinized cells) was added to the cell pellet and mixed by pipetting to get a homogeneous lysate. Then, 0.1 ml of chloroform was added to the tissue homogenate (or cell lysate), and the resulting mixture was vortexed for 15 sec. Following centrifugation (12 000 3 g for 15 min at 48C), the aqueous phase was transferred into a clean tube. Isopropanol at the same volume of the aqueous phase was added to samples, and the resulting mixture (upside-down several times) was kept on ice for 10 min. Following centrifugation (12 000 3 g for 15 min at 48C), the supernatant was discarded, and the RNA pellet was washed with 0.5 ml of 75% ethanol twice. After airdrying, the RNA pellet was dissolved in 20-30 ll of RNase-free water. The resultant RNA samples were then quantified using NanoDrop-2000 (Thermo Scientific). RNA samples were stored at À808C until further application.
Total RNA with good purity (A260/A280: 1.80-2.10) and integrity was reverse transcribed using a PrimeScript RT reagent kit with a gDNA eraser (RR047A; TaKaRa). For each sample, 1 lg of RNA was treated with gDNA eraser at 428C for 2 min to remove genomic DNA contamination. Then, a mixture for the reverse transcription was prepared and set at a program of 378C for 15 min and 858C for 5 sec to obtain the final cDNA samples. The cDNA samples were stored at À208C.
Quantitative Real-Time PCR Assay
The master mix for one reaction of a real-time PCR was made using 3 ll of RNase-free water, 5 ll of SYBR Primer ExTaq, 0.2 ll of dye, 0.4 ll of 10 lmol/L forward primer, and 0.4 ll of 10 lmol/L reverse primer. The master mix was mixed by vortexing and was aliquoted at 9 ll for each reaction in a well of a MicroAmp Optical 384-well Reaction Plate (Applied Biosystems). A total of 1 ll of 10 ng/ll sample cDNA was added last to its respective wells. ABI Prism 7900 (Applied Biosystems) was used to run the PCR reaction with 1 cycle of 958C for 10 sec, and 40 cycles each of 958C for 5 sec and 608C for 30 sec. The primer sequences used to amplify IGFBP1 were as follows: human, forward 5 0 -TCCTCCTCAGTTATCTCCGTG-3 0 ; reverse 5 0 -CTGCGTGCAG GAGTCTGA-3 0 ; and mouse, forward 5 0 -CTCTCAGAAAGCTCATCCGC-3 0 ; reverse 5 0 -TGTGTACCAGAACCTGCTGC-3 0 . The threshold cycles (Ct) were determined in triplicate for each sample, and the results were standardized with those from the internal reference genes GAPDH (human) or beta-2 microglobulin (B2m; mouse). The primer sequences used were as follows: GAPDH, forward 5 0 -CAGGGCTGCTTTTAACTCTGG-3 0 ; reverse 5 0 -TGGGTGGAAT CATATTGGAACA-3 0 ; and B2m, forward 5 0 -TTCAGTATGTTCGGCT TCCC-3 0 ; reverse 5 0 -TGGTGCTTGTCTCACTGACC-3 0 . The relative mRNA expression levels were calculated using the 2 À44Ct method. In our preliminary real-time PCR assays, we observed a stable GAPDH and B2m expression across all of the groups/treatments (coefficient of variation: ,15% for GAPDH and ,10% for B2m). Additionally, a similar PCR efficiency for each gene (95%-105%) was observed in our PCR analyses.
Western Blot Assay
Proteins were extracted from placental tissues, liver tissues, and HepG2 cells using RIPA buffer ( 
Immunohistochemistry Assay
Placenta and liver tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 4 lm. The slides were blocked in 5% bovine serum albumin and incubated with rabbit anti-IGFBP1 primary antibody (1:200; sc-
with diaminobenzidine (Dako Cytomation), counterstained with hematoxylin, dehydrated, and mounted in di-n-butyl phthalate xylene. Immunostained sections were quantified by digital image analysis with Image Pro-Plus 6.0 as we described previously [18] .
Statistical Analysis
All statistical analysis was performed with the SPSS 19.0 statistics package (SPSS). Nested ANOVA was performed to compare birth weight and IGFBP1 levels among control and E 2 -exposed groups. A generalized estimating equations approach with repeated measures was applied to account for the three pups of the same dam. One-way ANOVA was applied to compare maternal E 2 concentration after E 2 exposure and IGFBP1 expression in hepatocytes following E 2 treatment. When significant terms were present Tukey post hoc pairwise comparisons were conducted. The data were shown as mean 6 SD. A value of P , 0.05 was considered as statistically different.
RESULTS
Establishment of the Mouse Model of Fetal High-Estrogen Exposure
The pregnant mice were administrated orally with Ev during early pregnancy to achieve fetal high-E 2 exposure. To confirm the existence of high-E 2 exposure we examined the serum E 2 concentration on Day 11 of pregnancy. Compared with controls, E 2 level was significantly increased in the Ev50, Ev100, and Ev300 groups (P , 0.05), but not in the Ev10 group (Fig. 1A) . In spite of the increased risk of miscarriage in the Ev100 group, successful term deliveries were obtained. However, in the Ev300 group, the miscarriage rate was too high to have live pups. Therefore, the Ev100 group was selected as the high-E 2 exposure group. There were no significant differences in litter size and gestational time between the control and the high-E 2 exposure Ev100 groups (P . 0.05).
High E 2 Exposure During Early Pregnancy Decreased the Birth Weight and the Growth of the Offspring
Similar weights were observed for all of the fetuses or pups from each dam, whereas the birth weight of Ev100 pups was significantly lower than that of the control group, both on D18 of gestation and on D1 after birth (P , 0.05; Fig 1B) . There was no significant difference in birth weight between the control group and the Ev10 group (P . 0.05).
In Figure 1C , the body weight of pups with fetal high-E 2 exposure (Ev100) was significantly lower than that without exposure within 5 wk after birth (P , 0.05). After 5 wk, the difference gradually reduced. The body weight of 8-wk-old mice after high E 2 exposure was still lower than that without exposure, but the significance disappeared (P . 0.05) as a result of the reduced difference between two groups and the increased variance.
Expression of IGFBP1 in Placentae Was Up-regulated by Fetal High-E 2 Exposure
The mRNA expression of Igfbp1 was detected by real-time PCR (Fig. 2A) , and the result showed that high-E 2 exposure significantly up-regulated the mRNA expression of Igfbp1 in placenta (P , 0.05). In line with the mRNA expression, the protein expression of IGFBP1 in placentae was also elevated significantly in the pups with fetal high-E 2 exposure (P , 0.05; Fig. 2B ).
Immunohistochemistry assay was carried out to examine the cellular location of the IGFBP1 in placentae. As shown in FIG. 1 . Establishment of mouse model of high-E 2 exposure. A) E 2 concentration of D11. E 2 levels in the Ev50, Ev100, and Ev300 groups were significantly higher than that in the control group. B) Birth weight. Body weight on D18 of gestation represents birth weight of pups delivered by cesarean delivery. In both cesarean and natural deliveries, birth weight in the Ev100 group was significantly lower than that in the control group. C) Body weight after birth. Body weight in the high-E 2 exposure group was significantly lower than that in the control group from 1 to 5 wk. After that the difference gradually disappeared. *P , 0.05, compared with control group. Data were presented as mean 6 SD. Figure 2C , immunoreactivity of IGFBP1 located in both the cytoplasm and the nucleus, mainly in the cytoplasm. It was expressed mainly in trophoblast cells and decidual cells. IGFBP1 staining was stronger in the amnion/chorionic plate than in the labyrinth zone. Similarly, the expression of IGFBP1 in high-E 2 -exposed placentae appeared stronger than that in control (P , 0.05).
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Expression of IGFBP1 in Liver Tissues Was Up-regulated by Fetal High-E 2 Exposure
On D18 of pregnancy, mRNA expression of Igfbp1 in fetal liver increased significantly after high-E 2 exposure (P , 0.05). At 3 wk and 8 wk after birth, there was no significant difference in mRNA expression of Igfbp1 in the offspring's liver between the two groups, although a similar trend was observed between the two groups (P . 0.05; Fig. 3A) . Compared with the control group, the hepatic protein expression of IGFBP1 in the high-E 2 -exposed group was significantly up-regulated on D18 of pregnancy (P , 0.05), and the significance gradually disappeared after birth, at 3 wk and 8 wk (P . 0.05; Fig. 3B ).
Immunohistochemistry assay was performed to identify the cellular locations of IGFBP1 protein in the liver of mice. As shown in Figure 3C , IGFBP1 was mainly in cytoplasm. It was distributed evenly in hepatocytes throughout the hepatic parenchyma. The staining of IGFBP1 at D18, but not at 3 wk and 8 wk, in high-E 2 -exposed liver was stronger than that in control (P , 0.05).
E 2 Up-regulated IGFBP1 in Hepatocytes In Vitro
Given that IGFBP1 is mainly secreted by liver, we employed hepatocyte HepG2 to examine the effect of E 2 on the expression of IGFBP1. HepG2 cells were cultured in a medium containing different concentrations of E 2 for 24 h. As shown in Figure 4A , E 2 (10 À9 to 10 À5 M) dose-dependently increased IGFBP1 mRNA expression (P , 0.05), which peaked at 10 À7 M. Importantly, the elevation of IGFBP1 expression induced by E 2 was blocked by pretreatment with estrogen receptor antagonist ICI 182780. Consistent with the mRNA expression pattern, 10
À7 M E 2 significantly increased IGFBP1 protein expression level (P , 0.05), and such induction was almost abolished by pretreatment with ICI 182780. Taken together, above data suggest that E 2 upregulates IGFBP1 expression through an estrogen receptordependent pathway.
DISCUSSION
Recently there have been expanding concerns that the disrupted endocrine environment might impair the growth of the fetus and lead to chronic adult diseases in later life [19] . One example is that fetal exposure to a high level of estrogens has long-term consequences regarding the development of cardiovascular dysfunctions [20] , thyroid dysfunction [21] , dyslipidemia [17] , and breast cancer [22] . We have previously demonstrated that the maternal high-E 2 environment in early pregnancy correlates with increased risks of LBW in humans [7] . In this study, we developed a mouse model to further prove this causal relationship.
In order to balance the confounders thoroughly, we adopted exogenous E 2 supplementation, instead of controlled ovarian hyperstimulation, to establish the high-E 2 model, and thus the sole variance between the two groups was the E 2 level in early pregnancy. In this study, the serum E 2 concentration in the Ev100 group was about three times that in the control group. In our previous studies, the mean levels of serum E 2 of mothers in the fresh ET group were 2-to 3-fold higher than those in the NC group [7, 17, 21] . Therefore, the E 2 environment in this animal model could mimic the maternal high-E 2 environment present in in vitro fertilization treatment. With this model, we confirmed that the loss of birth weight is due to fetal highestrogen exposure. Notably, we observed that the weight of
FIG. 3. Expression of IGFBP1 in liver.
A) The mRNA expression of Igfbp1 was increased after maternal high-E 2 exposure. B) Protein expression of IGFBP1 was increased after maternal high-E 2 exposure. C) Cellular location and expression of IGFBP1 in liver. Staining of IGFBP1 in liver increased after high-E 2 exposure. *P , 0.05, compared with control group. Data were presented as mean 6 SD. Bar ¼ 50 lm and applies to all panels. C, control; E 2 , high-E 2 exposed.
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pups with fetal high-estrogen exposure was reduced before and after birth, highlighting the impact of fetal high-E 2 exposure on the weight of the offspring.
For the first time we have demonstrated that fetal high-E 2 exposure may cause the reduction of birth weight. Previous studies from other groups have suggested that the ovarian stimulation-induced maternal environment may be involved in the increased risk of LBW [6, [8] [9] [10] [23] [24] [25] [26] , and our previous study and some reports proposed that fetal high-E 2 exposure is correlated with LBW [7, 25, 26] . Estradiol benzoate had negative effects on rat placenta and caused FGR [27, 28] . Exposure to 17-alpha-ethinylestradiol during pregnancy impacted whole-embryo development and led to growth retardation [29] . In this study we have provided direct evidence to support a cause-and-effect relationship between fetal highestradiol exposure and LBW by means of a mouse maternal high-E 2 exposure model.
The present study of mice indicated that reduction of body weight is persisted at 5 wk after birth. In SGA children, catchup growth occurred between birth and 36 mo, mainly during the first year of life [30] , but children with SGA continued to be underweight at the age of 3 yr and 7 yr [31] . Adults born SGA were 2.35 cm shorter (95% confidence interval: 1.93, 2.77 cm) and 0.78 kg/m 2 thinner (95% confidence interval: 0.49-1.06 kg/m 2 ) [32] . All of the above indicate that reduced birth weight can have long-term effects on growth and development, and it requires sufficient attention.
In the present study we further discovered that both the mRNA and protein expressions of IGFBP1 were increased in the placentae in response to fetal high-estrogen exposure, supporting a notion that IGFBP1 may be involved in the occurrence of LBW after exposure to a high-E 2 environment. IGFs, similar to insulin, play important roles in the metabolisms of glycogen, protein, lipid, and carbohydrate, and in the growth and development of the fetus [33] . IGFBP1 is the predominant IGF-1 and IGF-2 binding protein and modulates bioactivities of IGFs. IGFBP1 binds IGFs, decreases the level of free IGFs, and restricts the biological activities of IGFs. It has been reported that the increased circulating and placental gene and protein expressions correlate with FGR [14, 15, [34] [35] [36] . Our results are in line with the former studies, and furthermore demonstrate that increased expression of IGFBP1 is associated with the risk of LBW after high-E 2 exposure. In contrast, the decreased circulating and placental levels of IGFBP1 were also reported in FGR pregnancies [37, 38] , indicating that dysregulation of IGFBP1, including decrease or increase, is related to abnormal fetal growth.
We have also observed that the expression of IGFBP1 in both placental and liver tissues is increased after exposure to a high-E 2 environment, and such an increase in HepG2 cells is abolished by pretreatment with an estrogen receptor antagonist, suggesting that E 2 regulates IGFBP1 through an estrogen receptor mechanism. The response of IGFBP1 expression to estrogen exposure is variable in the literature. In postmenopausal women estrogen therapy elevated the expression of IGFBP1 [39, 40] , whereas no influence was observed in later study [41] . In liver tissues, IGFBP1 secretion was increased by E 2 treatment [42] . This difference in the effect of estrogen on IGFBP1 level might be attributed to various subject selection criteria, E 2 treatment, and tissues examined in the different studies. Although further research is required to explore the exact mechanism of IGFBP1 regulation by E 2 , findings from the current study support that exposure to a high-E 2 environment up-regulates the IGFBP1 level in hepatocytes via estrogen receptor.
In conclusion, a maternal high-E 2 environment can lead to LBW, which was associated with elevated expression of IGFBP1. The decrease in body weight may continue after birth and increase some health risks. Therefore, monitoring E 2 level and limiting exogenous E 2 supplementation are required to improve the outcome of the offspring.
